History of major surgery within 30 days prior to trial initiation
Major surgery within 28 days of first dose AMG 757
No major surgery within 30 days of first study treatment.
Have had major surgery or bone fracture within 28 days before first dose of study treatment
Major surgery less than 28 days prior to study entry.
Major surgery within 21 days prior to first dose
Major surgery within 28 days prior to first dose of protocol therapy
Participants must be >= 28 days from any major surgery
Major hemorrhagic event within 28 days
Major surgery within 28 days prior to the first study treatment
Any major surgeries within 28 days.
Major surgery within 28 days prior to treatment or major surgery planned during the next 6 months
Has not had major surgery within 28 days prior to starting study treatment. Central venous access surgeries and/or placements would not be considered as major surgery.
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Major surgery within 21 days of starting protocol treatment
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Major surgery and surgery for brain metastases within 28 days prior to screening start; of note, intravenous port placement is not considered as a major surgery
Major surgery within 28 days of starting study treatment
Major surgery, radiotherapy or infection requiring therapy within 14 days of starting treatment
Patients with major surgery within 30 days prior to entering the study
Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment
At least 21 days have passed since major surgery
Any major surgery, chemotherapy or immunotherapy within the last 14 days
Major surgery within 28 days prior to C1D1.
Major surgery within 30 days prior or during the study period
Subject has had major surgery within 21 days prior to the first dose of ABBV-399.
Major surgery within 21 days prior to randomisation
Major surgery within 14 days before enrollment; the PI will serve as the final arbiter as to what constitutes major surgery
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Patients may have received prior surgery provided that at least 28 days have elapsed since major surgery (thoracic or other major surgeries) and the patient has recovered from all associated toxicities. Patients must have disease outside of the previous surgical resection area or a new lesion must be present.
Major surgery within 21 days prior to first dose
Patients with major surgery within 30 days prior to entering the study
Major surgery within 30 days before the initiation of study treatment
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Subject has had major surgery within the last 28 days
Patients who have had major surgery within the past 14 days.
214 Major surgery within 28 days of first dose AMG 562.
Major surgery within 14 days prior to study entry
Major surgery within 28 days prior to first study treatment.
Major surgery within 28 days of C1D1
Major surgery within 21 days of starting protocol treatment
Recent major surgery (within the past 14 days)
Ibrutinib must be discontinued 7 days before (when possible) until 7 days after major surgery, and 3 days before (when possible) until 3 days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery > 7 days before initiating treatment, and/or must have completed minor surgery > 3 days before initiating treatment
Patients may have received prior surgery (e.g., pleurectomy, pleurodeisis) provided at least 28 days have elapsed since surgery (thoracic or other major surgeries) and patients have recovered from all associated toxicities at the time of registration; there must be no anticipated need for major surgical procedures during protocol treatment
Patients must not have had major surgery within 28 days prior to registration or be scheduled for surgery during the projected course of protocol treatment; tumor biopsy is allowed
The participant underwent major surgery within 28 days.
Major surgery within 21 days of starting protocol treatment
Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment
Major surgery within 28 days before randomisation.
Any major surgery, chemotherapy or immunotherapy within the last 21 days
No major surgery within 28 days prior to treatment; no minor surgery within 5 days prior to treatment
Major surgery within 14 days before first dose or a scheduled surgery during study period; insertion of a venous access device (eg, catheter, port) is not considered major surgery.
Known need for major surgery within 14 days of the first dose of Ribociclib. Gastrostomy, insertion of a G tube, Ventriculo-peritoneal shunt, endoscopic ventriculostomy and central venous access are NOT considered major surgery.
Plan for any major surgery during treatment period.
Any major surgery =< 28 days prior to the initiation of investigational products
Subjects enrolling on the ibrutinib arm must not have had major surgery within 14 days, or minor surgery within 7 days
Patients may have received prior surgery (e.g., pleurectomy) provided that at least 28 days have elapsed since surgery (thoracic or other major surgeries) and patients have recovered (i.e., =< grade 1 or at baseline) from all associated toxicities at the time of registration; there must be no anticipated need for major surgical procedures during protocol treatment
Patients who have undergone major surgery within 7 days or minor surgery within 3 days of first dose of study drug
Major surgery within 30 days before study entry.
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Any major surgery or extensive radiotherapy within 28 days prior to screening
Patients who have had major surgery within 28 days prior to entry into the study or be recovering from any effects of surgery; patients who have had minor surgery within 2 weeks prior to entry into the study
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Major surgery within 28 days prior to the first dose of study medication
Major surgery within 30 days prior to the first dose of study treatment
Major surgery within 21 days prior to signing consent
PART B: Patients who have had major surgery within 28 days prior to entering the study or those who have not recovered from adverse events > grade 1 relating to the surgery
Patients with major surgery within 28 days prior to treatment
Patients with major surgery within 30 days prior to entering the study
Underwent major surgery within 14 days prior to first dose of ponatinib
Patients with major surgery within 30 days prior to entering the study
Any major surgery or extensive radiotherapy within 21 days of starting treatment on protocol
Major surgery or trauma occurring within 28 days of starting the trial
Major surgery within 28 days
Major surgery within 30 days of study medication
Major surgery within 21 days prior to the first dose of ABBV-838
Major surgery within 28 days of the first dose of study treatment
Patients may not begin protocol therapy within 7 days of major surgery or within 3 days of minor surgery
Major surgery requiring general anesthesia within 21 days or minor surgery within 14 days of study enrollment; subjects must have recovered from surgery related toxicities
Major surgery within 28 days
Plan for any major surgery during treatment period.
Ibrutinib must be discontinued 7 days before (when possible) until 7 days after major surgery, and 3 days before (when possible) until 3 days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery within 4 weeks before initiating treatment, and/or must have completed minor surgery > 3 days before initiating treatment
14 days must have elapsed since prior major surgery
Major surgery within 14 days before the first dose of study treatment.
Major surgery within 21 days prior to first dose
The subject had had major surgery within 28 days prior to the first dose of ABT-414.
Major surgery within 30 days
Major surgery within 21 days prior to first dose
Previous major surgery within 28 days prior to enrolment
Patients with major surgery within 30 days prior to entering the study
No major surgery within 28 days of study entry
Patients with major surgery within 28 days prior to treatment
Received major surgery (as defined by the Investigator), radiotherapy, or immunotherapy within 28 days of the first scheduled dose of MEDI7247.
Major surgery within <=28 days prior to the first dose of ABBV-085.
Patients who have had major non-biopsy surgery in the last 20 days.
Major surgery other than diagnostic surgery within 28 days